ReviewJournal of exercise rehabilitation2014
Role of adiponectin in metabolic and cardiovascular disease.
Review in Journal of exercise rehabilitation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Adiponectin and the risk of new-onset atrial fibrillation: a meta-analysis of prospective cohort studies.Bioscience reports · 2019Pooled it
- Effect of pravastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials.Drug design, development and therapy · 2019 · on this mapPooled it
- Antiobesity effect of Pediococcus pentosaceus LP28 on overweight subjects: a randomized, double-blind, placebo-controlled clinical trial.European journal of clinical nutrition · 2016Trial
- Inflammatory signalling in diabetic cardiomyopathy: molecular mechanisms and potential therapeutic strategies.Nature reviews. Cardiology · 2026Review
- Myovascular Niche: The Role of Endothelial Cells in Skeletal Muscle Health and Disease.Circulation research · 2026Review
- Longitudinal Adipokine and Lipid Profiles in Fabry Disease.Journal of clinical medicine · 2026Article
- Exosome-Based Proteomic Profiling for Biomarker Discovery in Pediatric Fabry Disease: Insights into Early Diagnosis Monitoring.Biomedicines · 2025Article
- Immune Microenvironment Dysregulation: A Contributing Factor to Obesity-Associated Male Infertility.Biomedicines · 2025Review
- Integrative Strategies for Preventing and Managing Metabolic Syndrome: The Impact of Exercise and Diet on Oxidative Stress Reduction-A Review.Life (Basel, Switzerland) · 2025Review
- Adiponectin targets the AMPK/mTOR signaling pathway to alleviate cognitive impairment in epilepsy.Molecular medicine reports · 2025Article
- Review
- Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines.Life (Basel, Switzerland) · 2024Review
- Soluble Fiber Effect on Human Serum Leptin and Adiponectin: A Systematic Review and Dose-Response Meta-Analysis.Clinical nutrition research · 2023Article
- Alcohol and Heart Failure.European cardiology · 2023Review
- The negative association of lower body fat mass with cardiometabolic disease risk factors is partially mediated by adiponectin.Endocrine connections · 2022Article
- Traditional and Emerging Sex-Specific Risk Factors for Cardiovascular Disease in Women.Reviews in cardiovascular medicine · 2022Review
- Adiponectin System (Rescue Hormone): The Missing Link between Metabolic and Cardiovascular Diseases.Pharmaceutics · 2022Review
- Developmental exposure to indoor flame retardants and hypothalamic molecular signatures: Sex-dependent reprogramming of lipid homeostasis.Frontiers in endocrinology · 2022Article
- Association of Adiponectin, Leptin and Resistin Plasma Concentrations with Echocardiographic Parameters in Patients with Coronary Artery Disease.Diagnostics (Basel, Switzerland) · 2021Article
- AdipoRon Attenuates Hypertension-Induced Epithelial-Mesenchymal Transition and Renal Fibrosis via Promoting Epithelial Autophagy.Journal of cardiovascular translational research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Under disease conditions including obesity (insulin resistance) and diabetes, dysregulation of adipokines such as tumor necrosis factor (TNF)-α, leptin, resistin, and adiponectin contribute to the development of metabolic and cardiovascular disease. Unlike other adipokines, adiponectin has been shown to be a therapeutic target for metabolic syndrome and cardiovascular disease. Circulating levels of adiponectin are markedly reduced in obese, diabetic, hypertensive, and coronary artery disease patients as well as experimental animal models of insulin resistance and diabetes. Recently, the small molecule adiponectin receptors (AdipoRs) agonist was discovered and suggested that the agonist is a novel therapeutic target for the treatment of type 2 diabetes linked to obesity in an experimental mouse model. This review will focus on signaling pathways involved in adiponectin and its receptors and the role of adiponectin in metabolic and cardiovascular disease including insulin resistance, cardiomyopathy, and cardiovascular dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.